Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Lonza Group Ltd.. (3/7/12). "Press Release: Lonza Signs Light Path Discovery Agreement with LegoChem Biosciences to Provide Pre-clinical Material of Novel Therapeutic Compound". Basel.

Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
Organisations Organisation Lonza Group AG (SWX: LONN)
  Today Lonza Group (Group)
  Group Lonza Group (Group)
  Organisation 2 LegoChem Biosciences, Inc. (KOSDAQ: 141080)
Products Product contract manufacturing (biologicals)
  Product 2 therapeutic antibody
Person Person White, Janet (Lonza 201109 Head Development Services)
     


> Contract covers Light Path™ Discovery Custom Material Supply for pre-clinical testing

> Protein production will be conducted at Lonza's Mammalian facility in Cambridge, UK

> Since the launch of Light Path™ in early 2011, Lonza has seen an increased demand for this unique offering focused on a reduced timeline to IND filing


Lonza announced today an agreement with Korean Biotech, LegoChem Biosciences, for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Under this agreement, Lonza will produce pre-clinical material using Light Path™ Discovery Services at its applied protein services facility in Cambridge, UK.

"Lonza's Light Path™ Discovery Services were specifically designed with the demands of preclinical assessment in mind," said Janet White, Head of Lonza's Development Services. "Lonza has built a strong reputation for CMO excellence. Today, we're also focusing efforts on supporting emerging biotechnology innovation at every stage of development to allow each customer the best chance for clinical success."

Woo, Sung Ho, Ph.D., Biology Director/Senior Vice President of LegoChem Biosciences said, "We have chosen to work with Lonza on this important project because of their reliability and solid reputation in field of mammalian development."

Lonza's Light Path™ Custom Material Services supports projects in their early phase, providing cGMP product within 11 months. In addition, Lonza's Light Path™ Discovery Service provides non-GMP product in 6 to 10 weeks, to support customers in the discovery testing phase. Since the launch of Light Path™ in early 2011, Lonza has seen an increased demand for this unique offering focused on a reduced timeline to IND filing. Light Path™ allows customers to reach their clinical milestones more efficiently.


About LegoChem Biosciences, Inc.

LegoChem Biosciences is a leading chemistry-based venture company in South Korea, working on the discovery and development of new small molecule drugs. LegoChem was established in May, 2006 by key members who has led the new drug R&D in Korea. It has investors such as Tong Yang investment Corp, Atinum Investment (formerly Hanmi investment Corp.), KDB Capital and Korea Investment Partners Co. For further information, please visit www.legochembio.com/en


About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.

Further Information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com


Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com


LegoChem Biosciences, Inc.
Woo, Sung Ho, Ph.D.
Biology Director/Senior Vice President
Tel +82-42-861-0688
Fax +82-42-861-0689
sungwoo@legochembio.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Lonza Group (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top